Related Experiment Video

Updated: Aug 19, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

[Advances in anti-epileptic treatment]

I Pascual-Castroviejo

    Anales Espanoles De Pediatria
    |September 1, 1983
    PubMed

    Insights

    Current epilepsy therapies, including cerebellar stimulation and antiepileptic drug monitoring, show limited success. Future advancements in epilepsy treatment may arise from research into receptors, neurotransmitters, and neuromodulators.

    Area of Science:

    • Neurology
    • Pharmacology

    Context:

    • Epilepsy treatment research faces challenges with existing therapeutic approaches.
    • Electrical stimulation of the cerebellar surface has yielded inconclusive results.
    • Monitoring antiepileptic drug levels has not provided definitive outcomes.

    Purpose:

    • To critically evaluate current therapeutic strategies for epilepsy.
    • To discuss the limitations of existing epilepsy treatments.
    • To explore potential future directions in epilepsy research.

    Summary:

    • The commentary highlights the insufficient outcomes from cerebellar electrical stimulation and antiepileptic drug level studies.
    • Valproic acid, while effective for specific indications, is not a universal solution for epilepsy.
    • Future progress in combating epilepsy may stem from investigating receptors, neurotransmitters, and neuromodulators.

    Impact:

    • Suggests a need for novel therapeutic targets in epilepsy management.
    • Emphasizes the importance of continued research into the neurobiological underpinnings of epilepsy.
    • Provides a critical perspective on current epilepsy drug trends and their limitations.

    More Related Videos

    Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis08:20

    Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis

    Published on: June 2, 2022

    Ex Vivo Calcium Imaging for Drosophila Model of Epilepsy04:41

    Ex Vivo Calcium Imaging for Drosophila Model of Epilepsy

    Published on: October 13, 2023

    Related Concept Videos

    Myasthenia Gravis: Overview and Treatment01:20

    Myasthenia Gravis: Overview and Treatment

    Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
    These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
    Alzheimer's Disease: Treatment01:22

    Alzheimer's Disease: Treatment

    Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
    Epilepsy and Seizures: Overview01:24

    Epilepsy and Seizures: Overview

    Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
    Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

    Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
    SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
    Electroconvulsive Therapy01:30

    Electroconvulsive Therapy

    Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
    Epilepsy ll: Types01:22

    Epilepsy ll: Types

    Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.